bioXcelerate AI’s PleioGraph Featured in BioPharm International

We’re thrilled to announce that bioXcelerate AI’s latest product, PleioGraph, was recently featured in BioPharm International. This advanced AI tool is designed to accelerate the drug discovery process by leveraging machine learning algorithms to analyse biological data. PleioGraph helps drug developers identify genetic colocalization – the interaction between genes, proteins, and cells that lead to disease. This allows researchers to better understand disease mechanisms, ultimately speeding up drug development and improving patient outcomes.

In the article, Dr Chris Foley, Chief Scientist and Managing Director of bioXcelerate, highlighted the growing challenge of analysing massive datasets in drug discovery. He explained how PleioGraph addresses these barriers by rapidly uncovering patterns hidden within data, offering a powerful tool for early-phase drug discovery. Dr Foley described the technology as an industry-leading solution that aims to improve efficiency and increase the chances of success in the pharmaceutical R&D process.

With rising R&D costs and declining returns on investment in the pharmaceutical industry, bioXcelerate’s PleioGraph is positioned to make a significant impact. By improving efficiencies and reducing the time to identify potential drug targets, the tool offers hope for developing new treatments more quickly and cost-effectively.

bioXcelerate AI, the health data division of Optima Partners, was founded by academics from leading UK universities and is committed to enhancing the pharmaceutical and biotech sectors through advanced data science and AI.

Read the full article here to learn more about how PleioGraph is transforming drug discovery.